Ken Griffin
FATE icon

Ken Griffin’s Fate Therapeutics FATE Stock Holding History

Ken Griffin’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.8K Sell
27,300
-5,900
-18% -$7.18K ﹤0.01% 12545
2025
Q4 		$32.6K Buy
33,200
+15,700
+90% +$18.9K ﹤0.01% 12200
2025
Q3 		$22.1K Buy
17,500
+4,100
+31% +$4.42K ﹤0.01% 12476
2025
Q2 		$15K Buy
13,400
+8,000
+148% +$9.3K ﹤0.01% 12158
2025
Q1 		$4.27K Sell
5,400
-10,500
-66% -$12.9K ﹤0.01% 13904
2024
Q4 		$26.2K Buy
15,900
+6,900
+77% +$17.4K ﹤0.01% 12988
2024
Q3 		$31.5K Sell
9,000
-5,000
-36% -$19.5K ﹤0.01% 12388
2024
Q2 		$45.9K Buy
14,000
+4,400
+46% +$19.3K ﹤0.01% 11857
2024
Q1 		$70.5K Sell
9,600
-1,200
-11% -$7.43K ﹤0.01% 11814
2023
Q4 		$40.4K Buy
10,800
+2,000
+23% +$4.72K ﹤0.01% 12002
2023
Q3 		$18.7K Sell
8,800
-13,600
-61% -$45.1K ﹤0.01% 12682
2023
Q2 		$107K Sell
22,400
-3,400
-13% -$18.8K ﹤0.01% 10841
2023
Q1 		$147K Sell
25,800
-4,600
-15% -$27.8K ﹤0.01% 10669
2022
Q4 		$307K Buy
30,400
+17,600
+138% +$331K ﹤0.01% 9268
2022
Q3 		$287K Sell
12,800
-100
-0.8% -$2.89K ﹤0.01% 9675
2022
Q2 		$320K Sell
12,900
-8,300
-39% -$229K ﹤0.01% 9662
2022
Q1 		$822K Buy
21,200
+2,100
+11% +$81.3K ﹤0.01% 8158
2021
Q4 		$1.12M Sell
19,100
-1,700
-8% -$96.4K ﹤0.01% 7684
2021
Q3 		$1.23M Buy
20,800
+3,300
+19% +$259K ﹤0.01% 7598
2021
Q2 		$1.52M Sell
17,500
-11,200
-39% -$903K ﹤0.01% 7288
2021
Q1 		$2.37M Buy
28,700
+800
+3% +$76.7K ﹤0.01% 6007
2020
Q4 		$2.54M Sell
27,900
-1,900
-6% -$118K ﹤0.01% 4862
2020
Q3 		$1.19M Buy
29,800
+5,200
+21% +$182K ﹤0.01% 5713
2020
Q2 		$844K Buy
24,600
+6,000
+32% +$179K ﹤0.01% 6145
2020
Q1 		$413K Sell
18,600
-12,100
-39% -$306K ﹤0.01% 6769
2019
Q4 		$601K Buy
+30,700
New +$488K ﹤0.01% 6511
2019
Q2 		– Sell
-19,400
Closed -$341K – 9358
2019
Q1 		$341K Buy
19,400
+300
+2% +$4.74K ﹤0.01% 7421
2018
Q4 		$245K Buy
+19,100
New +$266K ﹤0.01% 7580

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ken Griffin's FATE Position: Q1 2026 in Review

Ken Griffin increased its Fate Therapeutics (FATE) stake by 26% in Q1 2026, buying an estimated $236K and bringing the position to 942,926 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #7389.

Ken Griffin first reported a position in FATE in Q4 2015 and has held it in 34 quarters since. The position peaked at $112M in Q2 2020. 158 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Ken Griffin held 942,926 shares of Fate Therapeutics worth $1.13M as of Q1 2026.
  • Ken Griffin bought 193,590 Fate Therapeutics shares in Q1 2026, an estimated $236K.
  • Fate Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #7389 holding.
  • Ken Griffin first reported a position in Fate Therapeutics in Q4 2015 and has held it in 34 quarters since.
  • Ken Griffin's Fate Therapeutics position peaked at $112M in Q2 2020.
  • 158 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.